Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea To Bolster Fast-Track System With Speedier Approvals In Mind

This article was originally published in PharmAsia News

Executive Summary

With a broad ambition to improve the global competitiveness of its biopharma industry, South Korea is steadily unveiling supportive regulatory measures. Among the planned steps this year are the strengthening and clarification of an existing fast-track review and approval system, although the government says a limited number of reviewers may hamper the improved handling of such evaluations.

You may also be interested in...



Roche, GSK Face Compulsory Licensing Of Antivirals If Swine Flu Emergency Hits - South Korean Health Minister

SEOUL - Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) could be manufactured under compulsory licensing in South Korea if the country faces an emergency swine flu threat in the coming months, Health, Welfare and Family Affairs Minister Jeon Jae-Hee said

Helixmith Mods Engensis Trial Plans As Probe Unravels PK Anomalies

After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Topics

Related Companies

UsernamePublicRestriction

Register

SC089514

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel